ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

SKYE Skye Bioscience Inc

13.2101
0.1901 (1.46%)
Last Updated: 09:36:09
Delayed by 15 minutes

Period:

Draw Mode:

Volume 4,075
Bid Price 13.21
Ask Price 13.50
News -
Day High 13.51

Low
11.11

52 Week Range

High
17.6473

Day Low 13.20
Company Name Stock Ticker Symbol Market Type
Skye Bioscience Inc SKYE NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.1901 1.46% 13.2101 09:36:09
Open Price Low Price High Price Close Price Prev Close
13.20 13.20 13.51 13.02
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
23 4,075 $ 13.26 $ 54,019 - 11.11 - 17.6473
Last Trade Time Type Quantity Stock Price Currency
09:37:22 7 $ 13.3578 USD

Skye Bioscience Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 370.71M - - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Skye Bioscience News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No SKYE Message Board. Create One! See More Posts on SKYE Message Board See More Message Board Posts

Historical SKYE Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week13.5113.5112.5212.9432,965-0.2999-2.22%
1 Month13.5017.647311.1114.5270,011-0.2899-2.15%
3 Months13.5017.647311.1114.5270,011-0.2899-2.15%
6 Months13.5017.647311.1114.5270,011-0.2899-2.15%
1 Year13.5017.647311.1114.5270,011-0.2899-2.15%
3 Years13.5017.647311.1114.5270,011-0.2899-2.15%
5 Years13.5017.647311.1114.5270,011-0.2899-2.15%

Skye Bioscience Description

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. It researches and develops and plans to commercialize cannabinoid derivatives through its own directed research efforts and through several license agreements with the University of Mississippi. The company's lead compound, SBI-100, is initially being developed to treat ocular disease.

Your Recent History

Delayed Upgrade Clock